Metronidazol Eql Pharma

Metronidazole, the active ingredient in Metronidazol Eql Pharma, is a nitroimidazole antibiotic presented as an oral dosage form for systemic use. It treats infections caused by susceptible anaerobic bacteria and certain protozoa in adult patients, including conditions of the gastrointestinal, genitourinary and skin systems.

GNH USA supplies Metronidazol Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Metronidazole is used to treat infections caused by anaerobic bacteria and protozoal organisms.

- Anaerobic bacterial infections: effective against infections caused by anaerobic organisms, reducing bacterial load. - Bacterial vaginosis: restores normal vaginal flora by eliminating over‑growth of anaerobic bacteria. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Amoebiasis: eliminates intestinal Entamoeba histolytica, treating dysentery and liver abscesses. - Clostridioides difficile infection (adjunct therapy): used alongside standard therapy to reduce toxin‑producing bacteria.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: persistent metallic sensation in the mouth. - Headache: occasional throbbing headache. - Diarrhea: loose stools or increased frequency. - Abdominal cramps: intermittent stomach discomfort. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Seizures: convulsions, especially with high plasma levels. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering. - Liver toxicity: jaundice or elevated liver enzymes. - Neutropenia: marked reduction in white blood cells.

Before prescribing metronidazole, consider the following precautions.

- Pregnancy: consult a healthcare provider; safety category is not established. - Alcohol consumption: avoid alcohol to prevent a disulfiram‑like reaction. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic disease: monitor liver function and use with caution. - Drug interactions: review all concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Metronidazole can interact with several medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Alcohol: may cause severe nausea, vomiting, and flushing. - Warfarin: increased anticoagulant effect, risk of bleeding. - Lithium: heightened risk of lithium toxicity. - Cimetidine: may raise metronidazole plasma concentrations. - Phenobarbital: can reduce metronidazole efficacy.

Moderate Interactions (Monitor Closely): - Erythromycin: possible increase in metronidazole levels. - Benzodiazepines: enhanced sedative effect. - Phenytoin: may decrease metronidazole concentrations. - Oral contraceptives: potential reduction in contraceptive effectiveness.